Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (13214) 13214
Book Review (2341) 2341
Publication (821) 821
Newsletter (719) 719
Newspaper Article (586) 586
Magazine Article (112) 112
Book Chapter (97) 97
Conference Proceeding (96) 96
Reference (42) 42
Book / eBook (41) 41
Dissertation (37) 37
Transcript (11) 11
Government Document (9) 9
Web Resource (9) 9
Trade Publication Article (7) 7
Streaming Video (6) 6
Video Recording (2) 2
Archival Material (1) 1
Data Set (1) 1
Journal / eJournal (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (9264) 9264
humans (9070) 9070
thalidomide (8641) 8641
female (4508) 4508
male (4402) 4402
thalidomide - therapeutic use (3859) 3859
middle aged (3081) 3081
thalidomide - analogs & derivatives (2871) 2871
oncology (2829) 2829
aged (2667) 2667
multiple myeloma (2623) 2623
hematology (2606) 2606
multiple myeloma - drug therapy (2472) 2472
adult (2391) 2391
thalidomide - adverse effects (2327) 2327
thalidomide - administration & dosage (2169) 2169
animals (1950) 1950
treatment outcome (1934) 1934
bortezomib (1708) 1708
lenalidomide (1638) 1638
antineoplastic combined chemotherapy protocols - therapeutic use (1545) 1545
therapy (1506) 1506
thalidomide - pharmacology (1430) 1430
care and treatment (1256) 1256
cancer (1208) 1208
antineoplastic agents - therapeutic use (1174) 1174
research (1101) 1101
dexamethasone (1089) 1089
chemotherapy (1057) 1057
aged, 80 and over (1014) 1014
abridged index medicus (989) 989
stem-cell transplantation (978) 978
pharmacology & pharmacy (970) 970
drug therapy (928) 928
dexamethasone - administration & dosage (826) 826
pregnancy (826) 826
multiple-myeloma (823) 823
survival (806) 806
angiogenesis inhibitors - therapeutic use (798) 798
aids/hiv (792) 792
mice (792) 792
immunosuppressive agents - therapeutic use (759) 759
angiogenesis (750) 750
prognosis (704) 704
multiple myeloma - pathology (697) 697
multiple myeloma - therapy (691) 691
transplantation (671) 671
recurrence (650) 650
multiple myeloma - mortality (641) 641
medicine & public health (635) 635
health aspects (621) 621
analysis (618) 618
medicine, general & internal (609) 609
antineoplastic combined chemotherapy protocols - adverse effects (575) 575
disease-free survival (568) 568
trial (539) 539
retrospective studies (537) 537
risk factors (532) 532
rats (528) 528
dose-response relationship, drug (522) 522
dermatology (520) 520
abnormalities, drug-induced (519) 519
immunology (514) 514
clinical trials as topic (494) 494
drug therapy, combination (478) 478
necrosis-factor-alpha (476) 476
expression (474) 474
follow-up studies (472) 472
remission induction (458) 458
hematology, oncology and palliative medicine (457) 457
toxicology (452) 452
dosage and administration (449) 449
immunologic factors - therapeutic use (445) 445
survival analysis (445) 445
antineoplastic agents - adverse effects (444) 444
melphalan (437) 437
multiple myeloma - diagnosis (432) 432
drugs (431) 431
old medline (431) 431
combination (426) 426
time factors (426) 426
transplantation, autologous (422) 422
myeloma (415) 415
boronic acids - administration & dosage (412) 412
pyrazines - administration & dosage (411) 411
medical research (405) 405
survival rate (405) 405
antineoplastic combined chemotherapy protocols - administration & dosage (404) 404
disease progression (404) 404
clinical trials (399) 399
cells (398) 398
adolescent (394) 394
diagnosis (390) 390
multiple myeloma - complications (387) 387
plus dexamethasone (387) 387
stem cells (380) 380
boronic acids - therapeutic use (375) 375
pyrazines - therapeutic use (375) 375
combined modality therapy (373) 373
child (370) 370
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (17) 17
Robarts - Stacks (9) 9
UTL at Downsview - May be requested (7) 7
Online Resources - Online (5) 5
OISE - Stacks (4) 4
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Law (Bora Laskin) - May be requested in 6-10 wks (3) 3
St. Michael's College (John M. Kelly) - 2nd Floor (3) 3
Trinity College (John W Graham) - Stacks (3) 3
UofT at Scarborough - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Holland Bloorview Kids Rehabilitation - Stacks (2) 2
Media Commons - Audio Visual (2) 2
UofT at Mississauga - Stacks (2) 2
Criminology - Stacks (1) 1
East Asian (Cheng Yu Tung) - Stacks (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Law (Bora Laskin) - Stacks (1) 1
Music - Stacks (1) 1
New College (Ivey) - Stacks (1) 1
St. Augustine's Seminary - Stacks (1) 1
Victoria University E.J. Pratt - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (13089) 13089
German (484) 484
French (317) 317
Japanese (241) 241
Chinese (157) 157
Spanish (145) 145
Italian (85) 85
Portuguese (77) 77
Polish (70) 70
Czech (55) 55
Swedish (35) 35
Korean (34) 34
Dutch (25) 25
Russian (22) 22
Danish (14) 14
Hungarian (12) 12
Norwegian (8) 8
Finnish (7) 7
Hebrew (7) 7
Turkish (7) 7
Serbian (4) 4
Slovak (4) 4
Ukrainian (4) 4
Romanian (3) 3
Slovenian (3) 3
Bosnian (1) 1
Bulgarian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text 131
by Millrine, David and Ripley, Barry and Kishimoto, Tadamitsu
Cytokine, ISSN 1043-4666, 11/2014, Volume 70, Issue 1, p. 59
The Teratogenic properties of Thalidomide, in addition to its efficacy in the treatment of Multiple Myeloma, are dependent on Cereblon. Importantly however,... 
Thalidomide
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Dark remedy
: the impact of thalidomide and its revival as a vital medicine
by Stephens, Trent D and Brynner, Rock
2001, ISBN 0738204048, xii, 228
Thalidomide -- Research | Thalidomide | Thalidomide -- Side effects
Book
Details down arrow
3. Full Text Separation of [alpha]-glucosidase-inhibitory and liver X receptor-antagonistic activities of phenethylphenyl phthalimide analogs and generation of LXR[alpha]-selective antagonists
by Motoshima, Kazunori and Noguchi-Yachide, Tomomi and Sugita, Kazuyuki and Hashimoto, Yuichi and Ishikawa, Minoru
Bioorganic & Medicinal Chemistry, ISSN 0968-0896, 07/2009, Volume 17, Issue 14
Thalidomide
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
by Benboubker, Lotfi and Dimopoulos, Meletios A and Dispenzieri, Angela and Catalano, John and Belch, Andrew R and Cavo, Michele and Pinto, Antonello and Weisel, Katja and Ludwig, Heinz and Bahlis, Nizar and Banos, Anne and Tiab, Mourad and Delforge, Michel and Cavenagh, Jamie and Geraldes, Catarina and Lee, Je-Jung and Chen, Christine and Chen, Guang and Oriol, Albert and de la Rubia, Javier and Qiu, Lugui and White, Darrell J and Binder, Daniel and Anderson, Kenneth and Fermand, Jean-Paul and Moreau, Philippe and Attal, Michel and Knight, Robert and Van Oostendorp, Jason and Jacques, Christian and Ervin-Haynes, Annette and Avet-Loiseau, Hervé and Hulin, Cyrille and Facon, Thierry and FIRST Trial Team
The New England Journal of Medicine, ISSN 0028-4793, 09/2014, Volume 371, Issue 10, pp. 906 - 917
In patients ineligible for transplantation, the combination of lenalidomide and dexamethasone with lenalidomide maintenance until disease progression achieved... 
MEDICINE, GENERAL & INTERNAL | REFRACTORY MULTIPLE-MYELOMA | RESPONSE CRITERIA | CLINICAL-TRIALS | INITIAL TREATMENT | PREDNISONE PLUS THALIDOMIDE | RANDOMIZED CONTROLLED-TRIAL | QUALITY-OF-LIFE | STEM-CELL TRANSPLANTATION | ELDERLY-PATIENTS | BORTEZOMIB-MELPHALAN-PREDNISONE | Thalidomide - adverse effects | Prednisone - administration & dosage | Dexamethasone - administration & dosage | Humans | Middle Aged | Kaplan-Meier Estimate | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Multiple Myeloma - immunology | Thalidomide - administration & dosage | Disease-Free Survival | Thalidomide - analogs & derivatives | Melphalan - administration & dosage | Multiple Myeloma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged, 80 and over | Adult | Female | Aged | Dexamethasone | Patient outcomes | Multiple myeloma | Development and progression | Research | Comparative analysis | Drug therapy | Medical research | Chemotherapy | Transplants & implants | Melphalan | Clinical trials | Stem cell transplantation | Prednisone | Thalidomide | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity
by Schafer, P.H and Parton, A and Capone, L and Cedzik, D and Brady, H and Evans, J.F and Man, H.-W and Muller, G.W and Stirling, D.I and Chopra, R
Cellular Signalling, ISSN 0898-6568, 09/2014, Volume 26, Issue 9, pp. 2016 - 2029
Apremilast, an oral small molecule inhibitor of phosphodiesterase 4 (PDE4), is in development for chronic inflammatory disorders, and has shown efficacy in... 
Phosphodiesterase inhibitor | Apremilast | Spondyloarthropathies | Psoriasis | Preclinical drug evaluation | Psoriatic arthritis | PROTEIN-KINASE-A | CONTROLLED-TRIAL | CAMP-SPECIFIC PHOSPHODIESTERASE | NECROSIS-FACTOR-ALPHA | KAPPA-B | PSORIATIC-ARTHRITIS | CELL BIOLOGY | ORAL PHOSPHODIESTERASE-4 INHIBITOR | CYCLIC-AMP | THALIDOMIDE ANALOGS | B-MEDIATED TRANSCRIPTION | Thalidomide - metabolism | Humans | Male | Thalidomide - pharmacology | Lung Diseases - drug therapy | Thalidomide - analogs & derivatives | T-Lymphocytes - metabolism | T-Lymphocytes - drug effects | Female | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Cyclic AMP - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - chemistry | Vomiting - prevention & control | B-Lymphocytes - metabolism | Disease Models, Animal | Cell Line | Cytokines - metabolism | Immunity, Innate - drug effects | Jurkat Cells | Phosphodiesterase 4 Inhibitors - therapeutic use | Mice, Transgenic | Phosphodiesterase 4 Inhibitors - metabolism | Ferrets | Phosphodiesterase 4 Inhibitors - pharmacology | B-Lymphocytes - drug effects | Adaptive Immunity - drug effects | Animals | B-Lymphocytes - immunology | Protein Binding | T-Lymphocytes - immunology | Mice | Thalidomide - therapeutic use | Dendritic cells | Analysis | Development and progression | Genetic engineering | B cells | Biological response modifiers | T cells | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
by Richardson, Paul G and Schlossman, Robert L and Weller, Edie and Hideshima, Teru and Mitsiades, Constantine and Davies, Faith and Leblanc, Richard and Catley, Laurence P and Doss, Deborah and Kelly, Kathleen and McKenney, Mary and Mechlowicz, Julie and Freeman, Andrea and Deocampo, Reggie and Rich, Rebecca and Ryoo, Joan J and Chauhan, Dharminder and Balinski, Kathe and Zeldis, Jerome and Anderson, Kenneth C
Blood, ISSN 0006-4971, 11/2002, Volume 100, Issue 9, pp. 3063 - 3067
Thalidomide (Thai) can overcome drug resistance in multiple myeloma (MM) but is associated with somnolence, constipation, and neuropathy. In previous in vitro... 
THERAPEUTIC APPLICATIONS | ACTIVATION | DEXAMETHASONE | BONE-MARROW | GROWTH | THALIDOMIDE ANALOGS | TNF-ALPHA | INTERLEUKIN-6 | HEMATOLOGY | POTENT INHIBITORS | MARROW STROMAL CELLS | Adjuvants, Immunologic - administration & dosage | Adjuvants, Immunologic - pharmacology | Apoptosis - drug effects | Humans | Middle Aged | Salvage Therapy | Drug Resistance, Neoplasm | Male | Multiple Myeloma - immunology | Transplantation, Autologous | Thalidomide - pharmacology | Thalidomide - pharmacokinetics | Adjuvants, Immunologic - adverse effects | Adjuvants, Immunologic - pharmacokinetics | Dose-Response Relationship, Drug | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Adult | Female | Safety | Neutropenia - chemically induced | Adjuvants, Immunologic - therapeutic use | Thalidomide - adverse effects | Administration, Oral | Myeloma Proteins - analysis | Treatment Outcome | Combined Modality Therapy | Thrombocytopenia - chemically induced | Thalidomide - administration & dosage | Remission Induction | Constipation - chemically induced | Maximum Tolerated Dose | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Nervous System Diseases - chemically induced | Aged | Thalidomide - therapeutic use | Peripheral Blood Stem Cell Transplantation | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
by Zhu, Yuan Xiao and Braggio, Esteban and Shi, Chang-Xin and Bruins, Laura A and Schmidt, Jessica E and Van Wier, Scott and Chang, Xiu-Bao and Bjorklund, Chad C and Fonseca, Rafael and Bergsagel, P. Leif and Orlowski, Robert Z and Stewart, A. Keith
Blood, ISSN 0006-4971, 11/2011, Volume 118, Issue 18, pp. 4771 - 4779
The precise molecular mechanism of action and targets through which thalidomide and related immunomodulatory drugs (IMiDs) exert their antitumor effects... 
MULTIPLE-MYELOMA | THERAPY | IMPROVED SURVIVAL | THALIDOMIDE | IDENTIFICATION | IMIDS | HEMATOLOGY | Peptide Hydrolases - genetics | Humans | Pyrazines - administration & dosage | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Thalidomide - pharmacology | Dose-Response Relationship, Drug | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Biomarkers, Tumor - metabolism | Female | Antineoplastic Agents - pharmacology | Boronic Acids - administration & dosage | Drug Evaluation, Preclinical | Gene Expression Regulation, Neoplastic - physiology | Peptide Hydrolases - metabolism | Bortezomib | RNA, Small Interfering - pharmacology | Immunologic Factors - administration & dosage | Thalidomide - administration & dosage | Drug Resistance, Neoplasm - genetics | Comparative Genomic Hybridization | Models, Biological | Chromosome Aberrations | Cell Line, Tumor | Biomarkers, Tumor - genetics | Thalidomide - therapeutic use | Pyrazines - pharmacology | Biomarkers, Pharmacological - metabolism | Immunologic Factors - pharmacology | Multiple Myeloma - genetics | Boronic Acids - pharmacology | Drug Resistance, Neoplasm - drug effects | Immunologic Factors - therapeutic use | Index Medicus | Abridged Index Medicus | Lymphoid Neoplasia | Plenary Paper
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Structural basis of lenalidomide-induced CK1 alpha degradation by the CRL4(CRBN) ubiquitin ligase
by Petzold, G and Fischer, ES and Thoma, NH
NATURE, ISSN 0028-0836, 04/2016, Volume 532, Issue 7597, pp. 127 - 127
Thalidomide and its derivatives, lenalidomide and pomalidomide, are immune modulatory drugs (IMiDs) used in the treatment of haematologic malignancies(1,2).... 
MULTIPLE-MYELOMA | TARGET | CELLS | COMPLEX | ACTIVATION | DEL(5Q) MDS | IKAROS | QUANTIFICATION | MULTIDISCIPLINARY SCIENCES | THALIDOMIDE | CEREBLON | Ikaros Transcription Factor - chemistry | Catalytic Domain | Thalidomide - metabolism | Humans | Thalidomide - chemistry | Ubiquitin-Protein Ligases - metabolism | Models, Molecular | Crystallography, X-Ray | Structure-Activity Relationship | Thalidomide - pharmacology | Ubiquitin-Protein Ligases - chemistry | Proteolysis - drug effects | Thalidomide - analogs & derivatives | Substrate Specificity - drug effects | Ubiquitination - drug effects | Protein Binding - drug effects | Casein Kinase Ialpha - chemistry | Ikaros Transcription Factor - metabolism | Casein Kinase Ialpha - metabolism | Binding Sites - drug effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Thalidomide treatment down-regulates SDF-1[alpha] and CXCR4 expression in multiple myeloma patients
by Oliveira, Adriana Morgan and Maria, Durvanei Augusto and Metzger, Martin and Linardi, Camila and Giorgi, Ricardo Rodrigues and Moura, Fernanda and Martinez, Gracia Aparecida and Bydlowski, Sergio Paulo and Novak, Estela Maria
Leukemia Research, ISSN 0145-2126, 07/2009, Volume 33, Issue 7, pp. 970 - 973
The chemokine stromal-derived factor-1? (SDF-1?) and its receptor CXCR4 are critically involved in directional migration and homing of plasma cells in multiple... 
Thalidomide
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib
by Richardson, Paul G and Richardson, Paul G and Siegel, David and Siegel, David and Baz, Rachid and Baz, Rachid and Kelley, Susan L and Kelley, Susan L and Munshi, Nikhil C and Munshi, Nikhil C and Laubach, Jacob and Laubach, Jacob and Sullivan, Daniel and Sullivan, Daniel and Alsina, Melissa and Alsina, Melissa and Schlossman, Robert and Schlossman, Robert and Ghobrial, Irene M and Ghobrial, Irene M and Doss, Deborah and Doss, Deborah and Loughney, Nora and Loughney, Nora and McBride, Laura and McBride, Laura and Bilotti, Elizabeth and Bilotti, Elizabeth and Anand, Palka and Anand, Palka and Nardelli, Lisa and Nardelli, Lisa and Wear, Sandra and Wear, Sandra and Larkins, Gail and Larkins, Gail and Chen, Min and Chen, Min and Zaki, Mohamad H and Zaki, Mohamad H and Jacques, Christian and Jacques, Christian and Anderson, Kenneth C and Anderson, Kenneth C
Blood, ISSN 0006-4971, 2013, Volume 121, Issue 11, pp. 1961 - 1967
This phase 1 dose-escalation study determined the maximum tolerated dose (MTD) of oral pomalidomide (4 dose levels) administered on days 1 to 21 of each 28-day... 
SURVIVAL | CELLS | IMPACT | THERAPY | CC-4047 | PERIPHERAL NEUROPATHY | REVERSIBILITY | THALIDOMIDE ANALOGS | HEMATOLOGY | IMMUNOMODULATION | INHIBIT | Thalidomide - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bortezomib | Humans | Middle Aged | Pyrazines - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Treatment Outcome | Thalidomide - administration & dosage | Thalidomide - analogs & derivatives | Maximum Tolerated Dose | Multiple Myeloma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Treatment Failure | Aged, 80 and over | Adult | Female | Aged | Boronic Acids - administration & dosage | Thalidomide - therapeutic use | Drug Resistance, Neoplasm - drug effects | Index Medicus | Abridged Index Medicus | Clinical Trials and Observations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: Comparison of 2 dosing strategies in dual-refractory disease
by Lacy, Martha Q and Allred, Jacob B and Gertz, Morie A and Hayman, Suzanne R and Short, Kristen Detweiler and Buadi, Francis and Dispenzieri, Angela and Kumar, Shaji and Greipp, Philip R and Lust, John A and Russell, Stephen J and Dingli, David and Zeldenrust, Steven and Fonseca, Rafael and Bergsagel, P. Leif and Roy, Vivek and Stewart, A. Keith and Laumann, Kristina and Mandrekar, Sumithra J and Reeder, Craig and Rajkumar, S. Vincent and Mikhael, Joseph R
Blood, ISSN 0006-4971, 09/2011, Volume 118, Issue 11, pp. 2970 - 2975
Pomalidomide at doses of 2 or 4 mg/d has demonstrated excellent activity in patients with multiple myeloma (MM). We opened 2 sequential phase 2 trials using... 
MULTIPLE-MYELOMA | HEMATOLOGY | THALIDOMIDE | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Multiple Myeloma - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Pyrazines - therapeutic use | Boronic Acids - therapeutic use | Dose-Response Relationship, Drug | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Treatment Failure | Adult | Female | Thalidomide - adverse effects | Bortezomib | Dexamethasone - administration & dosage | Drug Administration Schedule | Administration, Oral | Treatment Outcome | Thalidomide - administration & dosage | Survival Analysis | Aged | Thalidomide - therapeutic use | Drug Resistance, Neoplasm - drug effects | Index Medicus | Abridged Index Medicus | Lymphoid Neoplasia | Clinical Trials and Observations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
by McCarthy, Philip L and Owzar, Kouros and Hofmeister, Craig C and Hurd, David D and Hassoun, Hani and Richardson, Paul G and Giralt, Sergio and Stadtmauer, Edward A and Weisdorf, Daniel J and Vij, Ravi and Moreb, Jan S and Callander, Natalie Scott and Van Besien, Koen and Gentile, Teresa and Isola, Luis and Maziarz, Richard T and Gabriel, Don A and Bashey, Asad and Landau, Heather and Martin, Thomas and Qazilbash, Muzaffar H and Levitan, Denise and McClune, Brian and Schlossman, Robert and Hars, Vera and Postiglione, John and Jiang, Chen and Bennett, Elizabeth and Barry, Susan and Bressler, Linda and Kelly, Michael and Seiler, Michele and Rosenbaum, Cara and Hari, Parameswaran and Pasquini, Marcelo C and Horowitz, Mary M and Shea, Thomas C and Devine, Steven M and Anderson, Kenneth C and Linker, Charles
The New England Journal of Medicine, ISSN 0028-4793, 05/2012, Volume 366, Issue 19, pp. 1770 - 1781
In patients who had undergone stem-cell transplantation, lenalidomide maintenance therapy improved progression-free and overall survival, though at the expense... 
INTERGROUPE FRANCOPHONE | MAINTENANCE | MEDICINE, GENERAL & INTERNAL | DEXAMETHASONE | RANDOMIZED PHASE-3 | ONCOLOGY-GROUP | RESPONSE CRITERIA | CONSOLIDATION THERAPY | IMPROVES SURVIVAL | THALIDOMIDE | BORTEZOMIB | Thalidomide - adverse effects | Double-Blind Method | Follow-Up Studies | Multiple Myeloma - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Neoplasms, Second Primary - epidemiology | Stem Cell Transplantation | Disease-Free Survival | Thalidomide - analogs & derivatives | Multiple Myeloma - drug therapy | Multiple Myeloma - therapy | Antineoplastic Agents - adverse effects | Adult | Female | Aged | Maintenance Chemotherapy | Thalidomide - therapeutic use | Drugs | Dose-response relationship (Biochemistry) | Care and treatment | Usage | Multiple myeloma | Stem cells | Product/Service Evaluations | Transplantation | Drug therapy | Autografts | Transplants & implants | Toxicity | Clinical trials | Stem cell transplantation | Cancer therapies | Cancer | Hemopoiesis | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Pharmacokinetics, metabolism and excretion of [14C]-lenalidomide following oral administration in healthy male subjects
by Chen, Nianhang and Wen, Lian and Lau, Henry and Surapaneni, Sekhar and Kumar, Gondi
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 3/2012, Volume 69, Issue 3, pp. 789 - 797
Assessment of the absorption, metabolism and excretion of [14C]-lenalidomide in healthy male subjects following a single oral dose.Six healthy male subjects... 
Absorption | Medicine & Public Health | Lenalidomide | Metabolite | Semen | Cancer Research | Oncology | Pharmacology/Toxicology | IMiD | Urinary excretion | REFRACTORY MULTIPLE-MYELOMA | MECHANISM | EFFICACY | LENALIDOMIDE PLUS DEXAMETHASONE | THALIDOMIDE | THERAPY | ONCOLOGY | IMMUNOMODULATORY DRUGS | PHARMACOLOGY & PHARMACY | IMIDS | MYELODYSPLASTIC SYNDROMES | Thalidomide - urine | Thalidomide - metabolism | Humans | Middle Aged | Biological Availability | Male | Metabolic Clearance Rate | Chromatography, High Pressure Liquid | Thalidomide - pharmacokinetics | Antineoplastic Agents - metabolism | Dose-Response Relationship, Drug | Tissue Distribution | Young Adult | Thalidomide - analogs & derivatives | Antineoplastic Agents - adverse effects | Adult | Antineoplastic Agents - pharmacokinetics | Molecular Structure | Thalidomide - adverse effects | Administration, Oral | Thalidomide - blood | Feces - chemistry | Antineoplastic Agents - urine | Adolescent | Antineoplastic Agents - blood | Carbon Radioisotopes | Index Medicus | Original
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide
by Larocca, Alessandra and Cavallo, Federica and Bringhen, Sara and Di Raimondo, Francesco and Falanga, Anna and Evangelista, Andrea and Cavalli, Maide and Stanevsky, Anfisa and Corradini, Paolo and Pezzatti, Sara and Patriarca, Francesca and Cavo, Michele and Peccatori, Jacopo and Catalano, Lucio and Carella, Angelo Michele and Cafro, Anna Maria and Siniscalchi, Agostina and Crippa, Claudia and Petrucci, Maria Teresa and Yehuda, Dina Ben and Beggiato, Eloise and Di Toritto, Tommaso Caravita and Boccadoro, Mario and Nagler, Arnon and Palumbo, Antonio
Blood, ISSN 0006-4971, 01/2012, Volume 119, Issue 4, pp. 933 - 939
Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism... 
TRIAL | PROPHYLAXIS | THERAPY | PLUS DEXAMETHASONE | VENOUS THROMBOSIS | PREVENTION | THALIDOMIDE | THROMBOEMBOLISM | HEMATOLOGY | CANCER | CHEMOTHERAPY | Pulmonary Embolism - prevention & control | Venous Thrombosis - chemically induced | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Enoxaparin - therapeutic use | Pulmonary Embolism - epidemiology | Enoxaparin - adverse effects | Incidence | Thalidomide - analogs & derivatives | Venous Thromboembolism - prevention & control | Multiple Myeloma - drug therapy | Antineoplastic Agents - adverse effects | Aspirin - adverse effects | Adult | Female | Venous Thrombosis - prevention & control | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Venous Thromboembolism - epidemiology | Platelet Aggregation Inhibitors - adverse effects | Thalidomide - adverse effects | Risk Factors | Anticoagulants - therapeutic use | Thalidomide - administration & dosage | Anticoagulants - adverse effects | Israel - epidemiology | Venous Thrombosis - epidemiology | Venous Thromboembolism - chemically induced | Italy - epidemiology | Pulmonary Embolism - chemically induced | Thalidomide - therapeutic use | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights